International
The Morning Science

What science found today

‹
 

Research

Enfortumab Vedotin and Pembrolizumab for Cisplatin-Eligible Bladder Cancer

NEJM ·

The Brief

  • A New England Journal of Medicine correspondence titled 'Enfortumab Vedotin and Pembrolizumab for Cisplatin-Eligible Bladder Cancer' was published.
  • It appears in Volume 395, Issue 20, pages 2073-2075, with an issue date of November 19, 2026.
  • The provided source contains only the title and citation, so no trial results or methods are available here.

Why it matters

The letter concerns combined enfortumab vedotin and pembrolizumab treatment for bladder cancer in patients who are eligible for cisplatin, a setting relevant to clinicians treating this disease. The source provided does not include its findings, so the practical implications cannot be assessed from it.

Who’s affected

  • oncologists and urologists treating bladder cancer
  • bladder cancer patients and their families

New England Journal of Medicine, Volume 395, Issue 20 , Page 2073-2075, November 19, 2026.

Timeline

  1. nejm.org

    Enfortumab Vedotin and Pembrolizumab for Cisplatin-Eligible Bladder Cancer

  2. Published in the New England Journal of Medicine, Volume 395, Issue 20, pages 2073-2075

How do you feel about this?

0 Comments

    Enfortumab Vedotin and Pembrolizumab for Cisplatin-Eligible Bladder Cancer – The Morning Science